Lv67
1870 积分 2024-12-24 加入
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
3天前
已完结
Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy
3天前
已完结
Deliberating the striking effect of dual GLP-1R and GIPR agonists on “Diabesity” in light of precision medicine and pharmacogenomics
3天前
已完结
Next Generation Dual GLP-1/GIP, GLP-1/Glucagon, and Triple GLP-1/GIP/Glucagon Agonists: A Literature Review
3天前
已完结
Transforming obesity: The advancement of multi-receptor drugs
3天前
已完结
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
3天前
已完结
GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale
10天前
已完结
Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice
10天前
已完结
Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice
10天前
已完结
Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance
10天前
已完结
皖公网安备34019202002308
